{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:38Z","timestamp":1792180658391,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["01EK1601A"],"award-info":[{"award-number":["01EK1601A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030859","name":"REBIRTH HANNOVER Forschungszentrum f\u00fcr translationale regenerative Medizin","doi-asserted-by":"publisher","award":["ZN3340"],"award-info":[{"award-number":["ZN3340"]}],"id":[{"id":"10.13039\/100030859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","award":["82DZL002A1"],"award-info":[{"award-number":["82DZL002A1"]}],"id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.addr.2025.115744","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:47:20Z","timestamp":1764694040000},"page":"115744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations"],"prefix":"10.1016","volume":"229","author":[{"given":"Alexandra","family":"Haase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Ruhparwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115744_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-031-34567-8_5","article-title":"United States Food and Drug Administration regulation of human cells, tissues, and gene therapies","volume":"1430","author":"Sanduja","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0010","author":"Current Good Manufacturing Practice (CGMP) Regulations, FDA"},{"key":"10.1016\/j.addr.2025.115744_bb0015","author":"Good manufacturing practice, EMA"},{"key":"10.1016\/j.addr.2025.115744_bb0020","author":"Advanced therapy medicinal products: Overview, EMA"},{"key":"10.1016\/j.addr.2025.115744_bb0025","author":"Regenerative Medical Products"},{"key":"10.1016\/j.addr.2025.115744_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.scr.2016.12.029","article-title":"Pluripotent cells display enhanced resistance to mutagenesis","volume":"19","author":"Cooper","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0035","author":"ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological\/biological products - Scientific guideline, EMA"},{"key":"10.1016\/j.addr.2025.115744_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/term.2021","article-title":"Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine","volume":"10","author":"Revilla","year":"2016","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081622","article-title":"A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells","volume":"8","author":"Goh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115744_bb0050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12015-018-9861-6","article-title":"An insight into DNA-free reprogramming approaches to generate integration-free induced pluripotent stem cells for prospective biomedical applications","volume":"15","author":"Borgohain","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nbt.3070","article-title":"A comparison of non-integrating reprogramming methods","volume":"33","author":"Schlaeger","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ymthe.2018.12.009","article-title":"mRNA-based genetic reprogramming","volume":"27","author":"Warren","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115744_bb0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1172482","article-title":"Human induced pluripotent stem cells free of vector and transgene sequences","volume":"324","author":"Yu","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115744_bb0070","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3788","article-title":"Derivation of induced pluripotent stem cells from human fibroblasts using a non-integrative system in feeder-free conditions","volume":"10","author":"Beltran","year":"2020","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.stem.2009.05.005","article-title":"Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins","volume":"4","author":"Kim","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.stem.2009.04.005","article-title":"Generation of induced pluripotent stem cells using recombinant proteins","volume":"4","author":"Zhou","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s12276-020-0383-3","article-title":"Small-molecule-mediated reprogramming: a silver lining for regenerative medicine","volume":"52","author":"Kim","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/hum.2012.203","article-title":"Mechanisms of retroviral integration and mutagenesis","volume":"24","author":"Cavazza","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2025.115744_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/15665232113136660006","article-title":"Biosafety challenges for use of lentiviral vectors in gene therapy","volume":"13","author":"Rothe","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2025.115744_bb0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.stem.2009.08.021","article-title":"Generation of induced pluripotent stem cells from human cord blood","volume":"5","author":"Haase","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101394","article-title":"GMP-compatible manufacturing of three iPS cell lines from human peripheral blood","volume":"35","author":"Haase","year":"2019","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.stem.2023.02.008","article-title":"Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming","volume":"30","author":"Liuyang","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0120","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41589-024-01799-8","article-title":"A rapid chemical reprogramming system to generate human pluripotent stem cells","volume":"21","author":"Wang","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.835321","article-title":"Creation of GMP-compliant iPSCs from banked umbilical cord blood","volume":"10","author":"Tian","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12967-023-03966-2","article-title":"Automating iPSC generation to enable autologous photoreceptor cell replacement therapy","volume":"21","author":"Bohrer","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.580352","article-title":"The StemCellFactory: a modular system integration for automated generation and expansion of human induced pluripotent stem cells","volume":"8","author":"Elanzew","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1089\/scd.2013.0621","article-title":"Vectorology and factor delivery in induced pluripotent stem cell reprogramming","volume":"23","author":"Hu","year":"2014","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.addr.2025.115744_bb0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/BA20040161","article-title":"The cryopreservation of human embryonic stem cells","volume":"41","author":"Heng","year":"2005","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.addr.2025.115744_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-1785-3_9","article-title":"Cryopreservation of human pluripotent stem cells: a general protocol","volume":"1235","author":"Miyazaki","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0155","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1093\/humrep\/den316","article-title":"Novel cryopreservation method for dissociated human embryonic stem cells in the presence of a ROCK inhibitor","volume":"23","author":"Martin-Ibanez","year":"2008","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.addr.2025.115744_bb0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bpc.2015.08.001","article-title":"Cryopreservation of cells: FT-IR monitoring of lipid membrane at freeze-thaw cycles","volume":"208","author":"Giugliarelli","year":"2016","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.addr.2025.115744_bb0165","author":"Cellular & Gene Therapy Guidances, FDA"},{"key":"10.1016\/j.addr.2025.115744_bb0170","author":"Stem cell-based medicinal products - Scientific guideline, EMA"},{"key":"10.1016\/j.addr.2025.115744_bb0175","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.stemcr.2023.05.003","article-title":"Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells","volume":"18","author":"Hirai","year":"2023","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0180","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","article-title":"ISSCR guidelines for stem cell research and clinical translation: the 2021 update","volume":"16","author":"Lovell-Badge","year":"2021","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0185","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2217\/rme-2018-0095","article-title":"Quality control guidelines for clinical-grade human induced pluripotent stem cell lines","volume":"13","author":"Sullivan","year":"2018","journal-title":"Regen. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13039-024-00698-w","article-title":"Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment","volume":"17","author":"Gazola","year":"2024","journal-title":"Mol. Cytogenet."},{"key":"10.1016\/j.addr.2025.115744_bb0195","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41596-021-00591-5","article-title":"Identification of cancer-related mutations in human pluripotent stem cells using RNA-seq analysis","volume":"16","author":"Lezmi","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-128-8_1","article-title":"Detection of mycoplasma contaminations","volume":"946","author":"Uphoff","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0205","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1038\/srep06996","article-title":"Computational image analysis of colony and nuclear morphology to evaluate human induced pluripotent stem cells","volume":"4","author":"Tokunaga","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1472-6750-11-102","article-title":"Authentication of African green monkey cell lines using human short tandem repeat markers","volume":"11","author":"Almeida","year":"2011","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0215","first-page":"3776","article-title":"Estimation of cell survival by flow cytometric quantification of fluorescein diacetate\/propidium iodide viable cell number","volume":"49","author":"Ross","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115744_bb0220","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cell.2010.12.032","article-title":"Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines","volume":"144","author":"Bock","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0230","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature09798","article-title":"Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells","volume":"471","author":"Lister","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115744_bb0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/gm284","article-title":"Transcriptomic analysis of pluripotent stem cells: insights into health and disease","volume":"3","author":"Yeo","year":"2011","journal-title":"Genome Med."},{"key":"10.1016\/j.addr.2025.115744_bb0240","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/stem.2797","article-title":"Concise review: assessing the genome integrity of human induced pluripotent stem cells: what quality control metrics?","volume":"36","author":"Assou","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2025.115744_bb0245","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12015-016-9662-8","article-title":"Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications","volume":"12","author":"Baghbaderani","year":"2016","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-024-08463-0","article-title":"Engineered heart muscle allografts for heart repair in primates and humans","volume":"639","author":"Jebran","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115744_bb0255","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.stem.2007.10.004","article-title":"The generation of six clinical-grade human embryonic stem cell lines","volume":"1","author":"Crook","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0260","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.scr.2016.08.011","article-title":"Development and production of good manufacturing practice grade human embryonic stem cell lines as source material for clinical application","volume":"17","author":"De Sousa","year":"2016","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035325","article-title":"Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications","volume":"7","author":"Tannenbaum","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115744_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.12.005","article-title":"Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update","volume":"32","author":"Kirkeby","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115744_bb0275","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115744_bb0280","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nmeth902","article-title":"Feeder-independent culture of human embryonic stem cells","volume":"3","author":"Ludwig","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.addr.2025.115744_bb0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nbt1177","article-title":"Derivation of human embryonic stem cells in defined conditions","volume":"24","author":"Ludwig","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm979","article-title":"Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor","volume":"10","author":"Sato","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0295","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nmeth.1593","article-title":"Chemically defined conditions for human iPSC derivation and culture","volume":"8","author":"Chen","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.addr.2025.115744_bb0300","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bit.21061","article-title":"Automated maintenance of embryonic stem cell cultures","volume":"96","author":"Terstegge","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2025.115744_bb0305","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/bit.22187","article-title":"Automated, scalable culture of human embryonic stem cells in feeder-free conditions","volume":"102","author":"Thomas","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2025.115744_bb0310","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nprot.2011.318","article-title":"Scalable expansion of human pluripotent stem cells in suspension culture","volume":"6","author":"Zweigerdt","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0315","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/sctm.20-0453","article-title":"High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling","volume":"10","author":"Manstein","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0320","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.scr.2016.02.027","article-title":"Targeted genome engineering using designer nucleases: state of the art and practical guidance for application in human pluripotent stem cells","volume":"16","author":"Merkert","year":"2016","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.scr.2017.07.010","article-title":"Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN","volume":"23","author":"Merkert","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.stemcr.2013.12.003","article-title":"Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells","volume":"2","author":"Merkert","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0335","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.omtm.2022.05.011","article-title":"Targeted biallelic integration of an inducible caspase 9 suicide gene in iPSCs for safer therapies","volume":"26","author":"Wunderlich","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2025.115744_bb0340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41232-023-00275-5","article-title":"Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy","volume":"43","author":"Aoki","year":"2023","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.addr.2025.115744_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","article-title":"Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application","volume":"26","author":"Kitano","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2025.115744_bb0350","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1038\/s41467-024-49400-z","article-title":"A scalable and cGMP-compatible autologous organotypic cell therapy for dystrophic epidermolysis bullosa","volume":"15","author":"Neumayer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115744_bb0355","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/crispr.2024.0028","article-title":"Enrichment of allelic editing outcomes by prime editing in induced pluripotent stem cells","volume":"7","author":"Niwa","year":"2024","journal-title":"CRISPR J."},{"key":"10.1016\/j.addr.2025.115744_bb0360","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/crispr.2022.0086","article-title":"Automated good manufacturing practice-compatible CRISPR-Cas9 editing of hematopoietic stem and progenitor cells for clinical treatment of beta-Hemoglobinopathies","volume":"6","author":"Urena-Bailen","year":"2023","journal-title":"CRISPR J."},{"key":"10.1016\/j.addr.2025.115744_bb0365","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41434-021-00259-5","article-title":"Automated production of CCR5-negative CD4(+)-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients","volume":"28","author":"Schwarze","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2025.115744_bb0370","article-title":"Delivery of gene editing therapeutics","volume":"54","author":"Kevadiya","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2025.115744_bb0375","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ymthe.2022.02.026","article-title":"Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells","volume":"30","author":"El-Kharrag","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115744_bb0380","doi-asserted-by":"crossref","first-page":"1459273","DOI":"10.3389\/fbioe.2024.1459273","article-title":"Automated CRISPR\/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory","volume":"12","author":"Niessing","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2025.115744_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41596-022-00753-z","article-title":"Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail","volume":"18","author":"Tristan","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/cpsc.123","article-title":"Methods for automated single cell isolation and sub-cloning of human pluripotent stem cells","volume":"55","author":"Vallone","year":"2020","journal-title":"Curr. Protoc. Stem Cell Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.613252","article-title":"Gene editing and genotoxicity: targeting the off-targets","volume":"2","author":"Blattner","year":"2020","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.addr.2025.115744_bb0400","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/bloodadvances.2020001977","article-title":"Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.addr.2025.115744_bb0405","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115744_bb0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nprot.2012.156","article-title":"Directed differentiation of human pluripotent cells to neural crest stem cells","volume":"8","author":"Menendez","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0415","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/nprot.2017.078","article-title":"Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation","volume":"12","author":"Nolbrant","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0420","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/7651_2015_310","article-title":"Generation of neural progenitor spheres from human pluripotent stem cells in a suspension bioreactor","volume":"1502","author":"Yan","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2025.115744_bb0425","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stemcr.2019.06.004","article-title":"Continuous WNT control enables advanced hPSC cardiac processing and prognostic surface marker identification in chemically defined suspension culture","volume":"13","author":"Halloin","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0430","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/nprot.2015.089","article-title":"Cardiac differentiation of human pluripotent stem cells in scalable suspension culture","volume":"10","author":"Kempf","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0435","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41596-024-00976-2","article-title":"Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks","volume":"19","author":"Kriedemann","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0440","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nprot.2012.150","article-title":"Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt\/beta-catenin signaling under fully defined conditions","volume":"8","author":"Lian","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0445","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41596-021-00560-y","article-title":"Generation of insulin-producing pancreatic beta cells from multiple human stem cell lines","volume":"16","author":"Hogrebe","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0450","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nprot.2014.059","article-title":"Directed differentiation of embryonic origin-specific vascular smooth muscle subtypes from human pluripotent stem cells","volume":"9","author":"Cheung","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0455","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.stemcr.2018.03.017","article-title":"Differentiation of human pluripotent stem cells into functional endothelial cells in scalable suspension culture","volume":"10","author":"Olmer","year":"2018","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0460","article-title":"Cell therapy with human iPSC-derived cardiomyocyte aggregates leads to efficient engraftment and functional recovery after myocardial infarction in non-human primates","author":"Gruh","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2025.115744_bb0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41596-021-00654-7","article-title":"Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors","volume":"17","author":"Ackermann","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0470","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41596-020-00470-5","article-title":"Production and cryopreservation of definitive endoderm from human pluripotent stem cells under defined and scalable culture conditions","volume":"16","author":"Sahabian","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115744_bb0475","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1089\/scd.2013.0088","article-title":"Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture","volume":"22","author":"Vosough","year":"2013","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.addr.2025.115744_bb0480","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41569-019-0331-x","article-title":"Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine","volume":"17","author":"Karbassi","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2025.115744_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061274","article-title":"Tissue-specific microparticles improve organoid microenvironment for efficient maturation of pluripotent stem-cell-derived hepatocytes","volume":"10","author":"Zahmatkesh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115744_bb0490","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcyt.2022.09.010","article-title":"Identification of marker genes to monitor residual iPSCs in iPSC-derived products","volume":"25","author":"Lemmens","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2025.115744_bb0495","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1038\/s41598-020-66845-6","article-title":"Robust detection of undifferentiated iPSC among differentiated cells","volume":"10","author":"Sekine","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0500","doi-asserted-by":"crossref","first-page":"239","DOI":"10.31083\/j.fbl2708239","article-title":"Universal markers for hiPSCs residue detection","volume":"27","author":"Shi","year":"2022","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.addr.2025.115744_bb0505","doi-asserted-by":"crossref","first-page":"16435","DOI":"10.1038\/s41598-023-43798-0","article-title":"Estimating residual undifferentiated cells in human chemically induced pluripotent stem cell derived islets using lncRNA as biomarkers","volume":"13","author":"Wu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0510","article-title":"Characterization of human induced pluripotent stems cells: current approaches, challenges, and future solutions","volume":"37","author":"Suresh Babu","year":"2023","journal-title":"Biotechnol. Rep. (Amst.)"},{"key":"10.1016\/j.addr.2025.115744_bb0515","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/srep04069","article-title":"A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells","volume":"4","author":"Tateno","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0520","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.scr.2015.01.009","article-title":"Development of a protein marker panel for characterization of human induced pluripotent stem cells (hiPSCs) using global quantitative proteome analysis","volume":"14","author":"Pripuzova","year":"2015","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115744_bb0525","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41467-018-04011-3","article-title":"Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells","volume":"9","author":"I. International Stem Cell","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115744_bb0530","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41467-017-01077-3","article-title":"DNA methylation and transcriptional trajectories during human development and reprogramming of isogenic pluripotent stem cells","volume":"8","author":"Roost","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115744_bb0535","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/rme-2022-0207","article-title":"International evaluation study of a highly efficient culture assay for detection of residual human pluripotent stem cells in cell therapies","volume":"18","author":"Watanabe","year":"2023","journal-title":"Regen. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/scd.2021.0255","article-title":"Distinctive clinical and pathologic features of immature teratomas arising from induced pluripotent stem cell-derived beta cell injection in a diabetes patient","volume":"31","author":"Han","year":"2022","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.addr.2025.115744_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030288","article-title":"iPS-cell technology and the problem of genetic instability-can it ever be safe for clinical use?","volume":"8","author":"Attwood","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115744_bb0550","unstructured":"Current Good Manufacturing Practice for Phase 1 Investigational Drugs FDA, 2008."},{"key":"10.1016\/j.addr.2025.115744_bb0555","author":"Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - Scientific guideline, EMA"},{"key":"10.1016\/j.addr.2025.115744_bb0560","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.stemcr.2020.09.002","article-title":"Comparison of 10 control hPSC lines for drug screening in an engineered heart tissue format","volume":"15","author":"Mannhardt","year":"2020","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2025.115744_bb0565","author":"Sterile Drug Products Produced by Aseptic Processing \u2014 Current Good Manufacturing Practice"},{"key":"10.1016\/j.addr.2025.115744_bb0570","author":"EU GMP Annex 1: Manufacture of Sterile Medicinal Products, European Commission"},{"key":"10.1016\/j.addr.2025.115744_bb0575","author":"Potency Assurance for Cellular and Gene Therapy Products, U.S. Food and Drug Administration"},{"key":"10.1016\/j.addr.2025.115744_bb0580","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.stem.2023.03.010","article-title":"Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy","volume":"30","author":"Marchiano","year":"2023","journal-title":"Cell Stem Cell"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:54:30Z","timestamp":1781600070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25002297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":116,"alternative-id":["S0169409X25002297"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115744","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115744"}}